Tackling inequalities: are secondary prevention therapies for reducing post-infarction mortality used without disparities?

Abstract

Background:

Mortality due to coronary heart disease has been declining as a result of better clinical patient management, including secondary prevention with the aid of effective drugs. The clinical challenge remains how to improve adherence to evidence-based cardiac care for all patients who can benefit from it. The present study aimed to assess the effectiveness of drug use after acute myocardial infarction (AMI) in reducing total medium-term mortality and to establish whether there are disparities in prescribing all therapies of demonstrated effectiveness.

Design:

We conducted a retrospective cohort study between 2002 and 2009 using a record linkage database, considering 1327 patients discharged after AMI.

Methods:

Cox’s regression models were used for the survival analysis with time-dependent variables. Logistic regression analyses were performed to investigate the inequalities in the actual use of therapies found significantly associated with a lower mortality in the survival analyses.

Results:

Therapies independently associated with a lower all-cause mortality risk were antiplatelet drugs, beta-blockers, angiotensin-converting enzyme inhibitors, and statins. Gender-related differences in prescriptions were seen for statins and antiplatelet drugs; age-related differences emerged for all drugs. Associated chronic obstructive pulmonary disease reduced the likelihood of patients taking the effective treatments.

Conclusion:

The present study revealed disparities in the use of treatments for the secondary prevention of coronary heart disease unjustifiable on the strength of clinical evidence.

Keywords

Acute myocardial infarction angiotensin-converting enzyme inhibitors antiplatelet drugs beta-blocker coronary heart disease healthcare disparities medical therapy management omega-3 secondary prevention statins

Get full access to this article

View all access options for this article.

References

Leal

Luengo-Fernández

Gray

. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27: 1610–1619.

Roger

Lloyd-Jones

. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2011 update: a report from the American Heart Association. Circulation 2011; 124: 426–426.

Chen

Cheng

Xiao

. Source effects of omega-3 fatty acid for sudden cardiac death prevention in patients with cardiovascular disease: a contemporary meta-analysis of randomized, controlled trials. Cardiovasc Drugs Ther 2011; 25: 259–265.

Shekelle

Rich

Morton

. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003; 41: 1529–1538.

Bhatt

Fox

Hacke

. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 20: 1706–1717.

Pedersen

Faergeman

Kastelein

. Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 16: 2437–2445.

Schwartz

Olsson

Ezekowitz

. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711–1718.

De Backer

Ambrosioni

Borch-Johnsen

. European Society of Cardiology. American Heart Association. American College of Cardiology. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Atherosclerosis 2004; 173: 381–391.

Dieppe

Bartlett

Davey

. Balancing benefits and harms: the example of non-steroidal anti-inflammatory drugs. BMJ 2004; 329: 31–34.

10.

Beauchamp

Peeters

Tonkin

. Best practice for prevention and treatment of cardiovascular disease through an equity lens: a review. Eur J Cardiovasc Prev Rehabil 2010; 17: 599–606.

11.

Dormuth

Schneeweiss

Brookhart

. Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis. Open Med 2008; 2: 74–82.

12.

Health Benchmarks Clinical Quality Indicator Specification 2009. Appropriate monitoring for angiotensin converting enzyme inhibitors, angiotensin reception blockers use. Measure: acearb401. Available at: http://www.bcbsil.com/provider/pdf/monitoring_arb.pdf.

13.

Austin

Mamdani

. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med 2006; 25: 2084–2106.

14.

Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383–1389.

15.

The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349–1357.

16.

Stenestrand

Wallentin

. Swedish Registry of Cardiac Intensive Care. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285: 430–436.

17.

Aronow

Topol

Roe

. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study. Lancet 2001; 357: 1063–1068.

18.

Newby

Kristinsson

Bhapkar

. SYMPHONY and 2nd SYMPHONY Investigators. Early statin initiation and outcomes in patients with acute coronary syndromes. JAMA 2002; 287: 3087–3095.

19.

Wei

Ebrahim

Bartlett

. Statin use in the secondary prevention of coronary heart disease in primary care: cohort study and comparison of inclusion and outcome with patients in randomised trials. BMJ 2005; 330: 821–821.

20.

Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ 2002; 324: 71–86.

21.

Freemantle

Cleland

Young

. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999; 318: 1730–1737.

22.

Kober

Torp-Pedersen

Carlsen

. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med 1995; 333: 1670–1676.

23.

Galan P, Kesse-Guyot E, Czernichow S, et al.; SU.FOL.OM3 Collaborative Group. Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo-controlled trial. BMJ 2010; 341: 6273.

24.

Kromhout D, Giltay EJ and Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010; 363: 2015–2026.

25.

EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554–572.

26.

Kotseva

Wood

De Backer

. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16(2): 121–237.

27.

Lee

Cooke

Robertson

. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008; 14: 271–280.

28.

Turnbull

Arima

Heeley

. Gender disparities in the assessment and management of cardiovascular risk in primary care: the AusHEART study. Eur J Cardiovasc Prev Rehabil 2011; 18: 498–503.

29.

Hansen

Hvelplund

Abildstrøm

. No gender differences in prognosis and preventive treatment in patients with AMI without significant stenoses. Eur J Cardiovasc Prev Rehabil 2012; 19(4): 746–754.

30.

Miettinen

Pyörälä

Olsson

. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation 1997; 96: 4211–4218.

31.

Truong QA, Murphy SA, McCabe CH, et al.; TIMI Study Group. Benefit of intensive statin therapy in women: results from PROVE IT-TIMI 22. Circ Cardiovasc Qual Outcomes 2011; 4: 328–336.

32.

Opotowsky

McWilliams

Cannon

. Gender differences in aspirin use among adults with coronary heart disease in the United States. J Gen Intern Med 2007; 22: 55–61.

33.

Tjia

Briesacher

Xie

. Disparities in combination drug therapy use in older adults with coronary heart disease: a cross-sectional time-series in a nationally representative US sample. Drugs Aging 2010; 27: 149–158.

34.

Reid

FDA

Cook

Whincup

. Use of statins in the secondary prevention of coronary heart disease: is treatment equitable? Heart 2002; 88: 15–19.

35.

Gnavi

Migliardi

Demaria

. Statins prescribing for the secondary prevention of ischaemic heart disease in Torino, Italy. A case of ageism and social inequalities. Eur J Public Health 2007; 17: 2–6.

36.

Deedwania

Stone

BaireyMerz

. Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE). Circulation 2007; 115: 700–707.

37.

Fleg

Aronow

Frishman

. Cardiovascular drug therapy in the elderly: benefits and challenges. Nat Rev Cardiol 2011; 8: 13–28.

38.

Gundersen

Abrahamsen

Kjekshus

. Timolol-related reduction in mortality and reinfarction in patients aged 65–75 years surviving acute myocardial infarction. Circulation 1982; 66: 1179–1184.

39.

Antiplatelet Trialists’ Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-1: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81–106.

40.

Walsh

. Statins as emerging treatments for asthma and chronic obstructive pulmonary disease. Expert Rev Resp Med 2008; 2: 329–335.

41.

Janda

Park

FitzGerald

. Statins in COPD: a systematic review. Chest 2009; 136: 734–743.

42.

Jost A, Rauch B, Hochadel M, et al.; HELUMA study group. Beta-blocker treatment of chronic systolic heart failure improves prognosis even in patients meeting one or more exclusion criteria of the MERIT-HF study. Eur Heart J 2005; 26: 2689–2697.

43.

Bauer T, Gitt AK, Jünger C, et al.; Acute Coronary Syndromes Registry (ACOS) investigators. Guideline-recommended secondary prevention drug therapy after acute myocardial infarction: predictors and outcomes of nonadherence. Eur J Cardiovasc Prev Rehabil 2010; 17(5): 576–581.

44.

Serebruany

Pokov

Kuliczkowski

. Incidence and causes of new-onset dyspnea in 3,719 patients treated with clopidogrel and aspirin combination after coronary stenting. Thromb Haemost 2008; 100: 314–318.

45.

Mancini

Etminan

Zhang

. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006; 47: 2554–2560.

46.

Mortensen

Copeland

Pugh

. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res 2009; 10: 45–45.

47.

Suissa

. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol 2008; 167: 492–499.